Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure

Palle B Jeppesen, Marek Pertkiewicz, Bernard Messing, Kishore Iyer, Douglas L Seidner, Stephen J D O'keefe, Alastair Forbes, Hartmut Heinze, Bo Joelsson

Research output: Contribution to journalArticlepeer-review

353 Citations (Scopus)


Teduglutide, a glucagon-like peptide 2 analogue, might restore intestinal structural and functional integrity by promoting growth of the mucosa and reducing gastric emptying and secretion. These factors could increase fluid and nutrient absorption in patients with short bowel syndrome with intestinal failure (SBS-IF). We performed a prospective study to determine whether teduglutide reduces parenteral support in patients with SBS-IF.
Original languageEnglish
Pages (from-to)1473-1481.e3
Issue number6
Publication statusPublished - Dec 2012


  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Biological Markers
  • Citrulline
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Endpoint Determination
  • Female
  • Humans
  • Injections, Subcutaneous
  • Intestinal Absorption
  • Intestinal Diseases
  • Intestines
  • Male
  • Middle Aged
  • Parenteral Nutrition
  • Peptides
  • Prospective Studies
  • Short Bowel Syndrome
  • Treatment Outcome
  • Video Recording
  • Young Adult

Cite this